Movement Alert｜HANSOH PHARMA Falls 3.1% in Regular Trading, Roche ADC deal momentum shows signs of cooling

Market Focus10-27

On October 27, HANSOH PHARMA fell 3.1% in Regular Trading, trading at HK$31.88, with turnover of HK$165 million.

The latest publicly discussed catalyst remains the company’s expanded ADC strategic collaboration and licensing agreement with Roche, but the current pullback suggests near-term trading enthusiasm after the deal announcement is being digested.

Under the agreement, HANSOH PHARMA will receive a $400 million upfront payment and a further $110 million on the first anniversary, and is eligible for more than $15 billion in development, regulatory and commercial milestones plus tiered royalties. The deal covers two preclinical ADC programs and additional projects based on HANSOH PHARMA’s proprietary ADC platform. Earlier broker commentary said the transaction improved visibility on global value monetization and validated the company’s ADC platform competitiveness, while the latest decline indicates that initial event-driven upside may be cooling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment